About Leuko -  www.leuko.com  |  careers@leuko.com

Leuko is an MIT spin-out developing PointCheckTM, the world’s first non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for multiple medically relevant situations, ranging from cancer chemotherapy management to the detection of life-threatening infections worldwide. Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device. Leuko’s vision is to empower patients and their loved ones, and make their lives better and safer by providing them with broad and immediate access to blood testing. Our groundbreaking technology has been awarded multiple awards including 1st prize at MassChallenge HealthTech and M2D2 Medical Device competitions. Leuko is a VC-backed (Series A) company and the recipient of a number of grants including a prestigious SBIR award from the National Cancer Institute.

Equality and Diversity Policy:

Leuko is an Equal Opportunity Employer and our employees are people with different strengths, experiences and backgrounds, who share a passion for improving people's lives. Diversity not only includes race and gender identity, but also age, disability status, veteran status, sexual orientation, religion and many other parts of one’s identity. All of our employee’s points of view are key to our success, and inclusion is everyone's responsibility.